Relexxii is a drug owned by Osmotica Pharmaceutical Us Llc. It is protected by 5 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 03, 2037. Details of Relexxii's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10695336 | Dose-dumping resistant controlled release dosage form |
Feb, 2037
(10 years from now) | Active |
| US10265308 | Dose-dumping resistant controlled release dosage form |
Feb, 2037
(10 years from now) | Active |
| US9855258 | Dose-dumping resistant controlled release dosage form |
Feb, 2037
(10 years from now) | Active |
| US9827234 | APPARATUS AND METHOD ARRANGED TO PROVIDE CONTROLLABLE WATER TREATMENT CUSTOMIZED TO THE CONDITIONS OF WATER SUPPLIED TO A BEVERAGE DISPENSER |
Feb, 2037
(10 years from now) | Active |
| US9707217 | SYSTEMS FOR DETERMINING FAULT LOCATION ON POWER DISTRIBUTION LINES |
Feb, 2037
(10 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Relexxii's patents.
Latest Legal Activities on Relexxii's Patents
Given below is the list of recent legal activities going on the following patents of Relexxii.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Jun, 2025 | US9855258 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 May, 2025 | US9827234 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Dec, 2024 | US9707217 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 30 Oct, 2024 | US9855258 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 30 Oct, 2024 | US9827234 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 12 Apr, 2024 | US9707217 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Dec, 2023 | US10695336 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 18 Sep, 2023 | US10695336 |
| Change in Power of Attorney (May Include Associate POA) | 17 Apr, 2023 | US10265308 |
| Electronic Review | 17 Apr, 2023 | US10265308 |
US patents provide insights into the exclusivity only within the United States, but
Relexxii is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Relexxii's family patents as well as insights into
ongoing legal events
on those patents.
Relexxii's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Relexxii's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 03, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Relexxii Generic API suppliers:
Methylphenidate Hydrochloride is the generic name for the brand Relexxii. 41 different companies have already filed for the generic of Relexxii, with Specgx Llc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Relexxii's generic
Alternative Brands for Relexxii
There are several other brand drugs using the same active ingredient (Methylphenidate Hydrochloride) as Relexxii. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Aytu Biopharma |
| |||
| Commave Therap |
| |||
| Ironshore Pharms |
| |||
| Janssen Pharms |
| |||
| Nextwave |
| |||
| Nextwave Pharms |
| |||
| Purdue Pharma Lp |
| |||
| Rhodes Pharms |
| |||
| Sandoz |
| |||
| Specgx Llc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Methylphenidate Hydrochloride, Relexxii's active ingredient. Check the complete list of approved generic manufacturers for Relexxii
About Relexxii
Relexxii is a drug owned by Osmotica Pharmaceutical Us Llc. Relexxii uses Methylphenidate Hydrochloride as an active ingredient. Relexxii was launched by Osmotica in 2022.
Approval Date:
Relexxii was approved by FDA for market use on 23 June, 2022.
Active Ingredient:
Relexxii uses Methylphenidate Hydrochloride as the active ingredient. Check out other Drugs and Companies using Methylphenidate Hydrochloride ingredient
Dosage:
Relexxii is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 18MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 72MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 63MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 54MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 45MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 36MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 27MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |